Apixaban Market – RegionalInsights
Based on the region, the global ApixabanMarket is segmented into North America, Europe, Latin America, AsiaPacific, Middle East, and Africa. North America holds the dominant position interms of revenue generated by the high price of the drug in treating venousthromboembolic events. For instance, according to GoodRx Inc. 2018 pricingdetail, 60 tablets of Eliquis 5mg cost around US$ 524.38 on an average in theU.S. Moreover, increasing prevalence of venous thromboembolic events hasboosted adoption of apixaban in North America market significantly. Forinstance, according to study published in the American Journal of PreventiveMedicine in 2010, venous thromboembolism (VTE) affects approximately300,000-600,000 people in the U.S. annually, causing considerable mortality.Furthermore, venous thromboembolism (VTE) disorder can occur in allethnicities, all age groups, and both genders.
Asia Pacific market is expectedto witness significant growth followed by Europe market over the forecastperiod, owing to increasing healthcare initiatives by respective governments.Moreover, a study published PLOS ONE 2016 showed, the cost effectiveness ofapixaban drug versus warfarin in Chinese patients with non-valvular atrialfibrillation in Hong Kong are some the factors that are also propelling thegrowth of apixaban market in the particular region.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1898
Apixaban is a Food and DrugAdministrator (FDA) approved anticoagulant used for the treatment of venousthromboembolic events (blood clot) that forms within a vein. Venousthromboembolic events (VTE) can occur without any prior symptoms or warningsigns and can go undiagnosed and unrecognized by a healthcare professional.Symptoms that do appear may be associated with pulmonary embolism (PE) oreither deep vein thrombosis (DVT) such as pain in the calf, swelling in theankle or foot, redness or noticeable discoloration spots, rapid breathing,chest pain, and others. Apixaban is sold under the trade-name of Eliquis.Factor Xa is a trypsin-like serine protease that plays a key role in bloodcoagulation cascade. Apixaban mechanism works on inhibiting factor Xa, whichindirectly decreases the clot formation stimulated by thrombin. Apixaban isindicated to reduce the risk of stroke and systemic embolism in patients withnonvalvular atrial fibrillation. The recommended dose of Eliquis is 5mg orallytwice a day. Apixaban is available in the market as capsules and tablet form.
Apixaban Market – Dynamics
Increasing prevalence of venousthromboembolism related conditions is expected to aid in growth of the apixabanmarket. For instance, according to International Society on Thrombosis andHaemostasis 2014 facts, revealed that around 10 million cases of venousthromboembolism occur annually across low, middle and high income countries.Moreover, increasing therapeutic indications for apixaban is expected to boostthe apixaban market growth. For instance, in 2014, the U.S. Food and DrugAdministration approved Eliquis for the treatment of deep vein thrombosis (DVT)prophylaxis and pulmonary embolism (PE) and also for the reduction in risk ofrecurrent PE and DVT following initial therapy. Furthermore, government andprivate organizations are significantly investing capital in healthcareresearch and development and this is also likely to propel growth of theApixaban market.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/apixaban-market-1898
However, adverse effects ofapixaban such as increased risk of thrombotic events after prematurediscontinuation and bleeding is expected to hamper adoption of this. This inturn is expected to adversely affect growth of the market. According to a studypublished in the Current Medical Research and Opinion 2017 stated about thebleeding risk associated with use of apixaban.
Apixaban Market – CompetitiveLandscape
Major players operating in theglobal apixaban market include Bristol-Myers Squibb, Portola Pharmaceuticals,C. H. Boehringer Sohn, Pfizer, Roche, CoaguSense, Siemens, Alere, and Abbott.Market players are focusing on developing new technologies, and on mergers, andcollaborations in order to gain dominant position in the market. For instance,in 2016, Pfizer and Bristol-Myers Squibb entered into collaboration withPortola Pharmaceuticals to commercialize and develop investigational AndexanetAlfa, a clinical phase 3 drug, which is developed to reverse the anticoagulanteffect of Factor Xa inhibitors that will be helpful for patients experience amajor bleeding issue on the use of Eliquis.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1898
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
